Ruconest, a recombinant human form of the C1 inhibitor protein, is more cost-effective than other on-demand therapies at…
Articles by Marisa Wexler, MS
New clinical trial data show that BioCryst Pharmaceuticals‘ investigational therapy for hereditary angioedema (HAE), berotralstat, reduces the frequency…
The European Commission has approved Pharming‘s Ruconest (conestat alfa) for the treatment of acute swelling episodes in…
Mutations in the KCNMA1 gene may predispose certain people to angioedema caused by blood pressure medications, a study suggests.
A new diagnostic test for hereditary angioedema (HAE) can measure the activity of C1-inhibitor (C1-INH) in a…
Bradykinin, a key molecular player involved in swelling attacks in hereditary angioedema patients, does so by signaling through…
In Italy, people with hereditary angioedema (HAE) types 1 or 2 are not at an increased risk of premature…
Researchers have developed a new tool that measures disease activity specifically in people with hereditary angioedema due to C1-inhibitor…
Researchers developed a questionnaire, called the Angioedema Control Test (AECT), that may be helpful in monitoring disease control and patient-reported…
A Thai version of the Angioedema Quality of Life (AE-QoL) questionnaire is a reliable way to measure health-related quality of…